arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Camp4 Therapeutics Corp

CAMP

$4.24 ▼ -0.21 (-4.61%) at close

4 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Camp4 Therapeutics Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $128.8M

Dividend Yield —

Revenue Growth 436.5% ↗

Op. Margin —

ROIC -87.0% ↘

FCF / Share $-0.98 ↗

Trailing P/E —

Price / Book 4.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.50M

↑ +436.5% —

Net Income Profit after all expenses

$-80.40M

↓ -55.2% —

FCF / Share Free cash flow per share

$-0.98

↑ +90.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2022

FY 2023

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	436.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5356%)	86.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+979%)	—	—
EPS Growth YoY (%)	76.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	91.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-55.2% Weak Weak Year-over-year change in net income	-5.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	90.0% Excellent Excellent Year-over-year change in free cash flow	91.4% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.37x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-87.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	33.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-44.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-67.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-94.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-168.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1224%)	-82.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-647%)	39.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+166%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-109.52M	$-64.04M	$-38.38M	—

📊 What does each share earn? 8 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.12	$0.14	$0.89	—
Basic EPS, GAAP (USD)	$-2.65	$-11.04	$-124.80	—
Free Cash Flow per Share (USD)	$-0.98	$-9.81	$-113.51	—
Dividend per Share (USD)	$0.00	—	—	—
Book Value per Share (USD)	$0.92	$3.13	$-268.57	—
Tangible Book Value per Share (USD)	$0.92	$3.13	$-268.57	—
Basic Weighted Avg Shares (shares)	30.38M	4.69M	394,976	—
Dividend Payout Ratio (%)	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$98.58M	$56.78M	$32.21M	—
Total Equity (USD)	$47.70M	$63.14M	$-123.73M	$-77.53M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$3.50M	$652.00K	$350.00K	—
Depreciation Expense (USD)	$1.64M	$1.70M	$1.68M	—
Net Income, GAAP (USD)	$-80.40M	$-51.79M	$-49.29M	—
Operating Cash Flow (USD)	$-29.55M	$-45.56M	$-44.16M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

Camp4 Therapeutics Corp

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CAMP with peers